SCHEMBL31562020

SCHEMBL31562020

C=CC(=O)N1CCC(=O)c2ccccc21

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.66
RAB9A P51151 2/20 0.66
HTT P42858 2/20 0.55
NOTUM Q6P988 2/20 0.49
KMT2A Q03164 3/20 0.44
MEN1 O00255 2/20 0.44
ALDH1A1 P00352 5/20 0.44
TSHR P16473 4/20 0.44
USP2 O75604 1/20 0.44
TP53 P04637 1/20 0.44
GSK3B P49841 2/20 0.43
BTK Q06187 2/20 0.40
CYP2D6 P10635 2/20 0.40
TET3 O43151 1/20 0.39
FBXL19 Q6PCT2 1/20 0.39
CXXC5 Q7LFL8 1/20 0.39
TET1 Q8NFU7 1/20 0.39
KDM2B Q8NHM5 1/20 0.39
CXXC4 Q9H2H0 1/20 0.39
KDM2A Q9Y2K7 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28021992 0.83 LMNA (0.68) LMNARAB9AHTTNOTUMKMT2A
SCHEMBL86823 0.80 RAB9A (0.44) LMNARAB9AHTTNOTUMKMT2A
SCHEMBL10899996 0.79 NOTUM (0.62) LMNARAB9AHTTNOTUMKMT2A
SCHEMBL9956661 0.79 LMNA (0.58) LMNARAB9AHTTNOTUMKMT2A
SCHEMBL68594 0.79 NOTUM (0.72) LMNARAB9AHTTNOTUMALDH1A1
SCHEMBL29611497 0.79 NOTUM (0.62) LMNARAB9AHTTNOTUMKMT2A
SCHEMBL842907 0.76 HPGD (0.64) LMNARAB9AHTTNOTUMKMT2A
SCHEMBL10869086 0.75 LMNA (0.55) LMNARAB9AHTTNOTUMKMT2A
SCHEMBL24131820 0.74 CDC7 (0.43) LMNARAB9AHTTBTK
SCHEMBL12723518 0.74 RAB9A (0.73) LMNARAB9AHTTNOTUMKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12570655-B2 Cysteine covalent modifiers of AKT1 and uses thereof TERREMOTO BIOSCIENCES, INC. (US) 2026-03-10 US disclosed
WO-2025081045-A9 CYSTEINE COVALENT MODIFIERS OF AKT1 AND USES THEREOF TERREMOTO BIOSCIENCES, INC. (US) 2025-12-26 WO disclosed
US-20250289819-A1 CYSTEINE COVALENT MODIFIERS OF AKT1 AND USES THEREOF TERREMOTO BIOSCIENCES, INC. 2025-09-18 US disclosed
WO-2025081045-A1 CYSTEINE COVALENT MODIFIERS OF AKT1 AND USES THEREOF TERREMOTO BIOSCIENCES, INC. (US) 2025-04-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12570655-B2 Cysteine covalent modifiers of AKT1 and uses thereof AKT1, AKT2, AKT3 LMNA 4448/4885RAB9A 470/4885HTT 3562/4885
US-20250289819-A1 CYSTEINE COVALENT MODIFIERS OF AKT1 AND USES THEREOF AKT1, AKT2, AKT3 LMNA 4238/4885RAB9A 686/4885HTT 2987/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.